American Journal of Cardiology
Volume 105, Issue 3 , Pages 343-351, 1 February 2010

Coronary Artery Bypass Grafting Versus Drug-Eluting Stent Implantation for Left Main Coronary Artery Disease (from a Two-Center Registry)

  • Si-Hyuck Kang, MD

      Affiliations

    • Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul, Republic of Korea
    • Drs S-H Kang and K-H Park contributed equally to the study.
  • ,
  • Kay-Hyun Park, MD, PhD

      Affiliations

    • Department of Thoracic Surgery, Seoul National University Bundang Hospital, Gyeonggido, Republic of Korea
    • Drs S-H Kang and K-H Park contributed equally to the study.
  • ,
  • Dong-Ju Choi, MD, PhD

      Affiliations

    • Department of Internal Medicine and Cardiovascular Center, Seoul National University Bundang Hospital, Gyeonggido, Republic of Korea
    • Corresponding Author InformationCorresponding author: Tel: (82) 31-787-7007; fax: (82) 32-787-7041
  • ,
  • Kyung Woo Park, MD, PhD

      Affiliations

    • Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul, Republic of Korea
  • ,
  • Woo-Young Chung, MD, PhD

      Affiliations

    • Department of Internal Medicine and Cardiovascular Center, Seoul National University Bundang Hospital, Gyeonggido, Republic of Korea
  • ,
  • Cheong Lim, MD, PhD

      Affiliations

    • Department of Thoracic Surgery, Seoul National University Bundang Hospital, Gyeonggido, Republic of Korea
  • ,
  • Ki-Bong Kim, MD, PhD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul, Republic of Korea
  • ,
  • Hyo-Soo Kim, MD, PhD

      Affiliations

    • Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul, Republic of Korea

Received 15 July 2009; received in revised form 22 September 2009; accepted 22 September 2009.

Recent studies have suggested that percutaneous coronary intervention (PCI) in patients with unprotected left main coronary artery (LMCA) disease renders outcomes comparable to those from coronary artery bypass grafting (CABG). It is necessary to stratify individual patient risk and select the optimal revascularization strategy. We compared the clinical outcomes of patients with unprotected LMCA disease who had undergone PCI with drug-eluting stents or CABG. We identified 462 patients who were treated from January 2003 to December 2006 for unprotected LMCA or LMCA-equivalent disease: 257 had undergone CABG and 205 had undergone PCI with drug-eluting stents. Analyses using propensity scores were performed to minimize the selection bias in the present observational study. After a median follow-up of 33.5 months, no significant difference was found between the CABG and PCI groups in the risk of death (12.1% vs 14.1%, respectively; p = 0.428) or the risk of a composite of death, myocardial infarction, or cerebrovascular accident (17.5% vs 20.0%, respectively; p = 0.434). The rate of major adverse cardiac and cerebrovascular events was significantly lower in the CABG group than in the PCI group (21.8% vs 35.1%, respectively; p = 0.001); the difference was mainly driven by a decrease in the rate of repeat revascularizations (5.1% vs 22.4%; p <0.001). The analyses after propensity score adjustment and matching corroborated the crude group results. In conclusion, PCI with drug-eluting stents showed a safety profile comparable to that of CABG in patients with unprotected LMCA disease. However, the risk of repeat revascularization was significantly greater in the PCI group.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This study was supported by grant A062260 from the Innovative Research Institute for Cell Therapy, Department of Internal Medicine, Seoul National University/Cardiovascular Center, Seoul, Republic of Korea, and grant 0412-CR02-0704-0001 from the Clinical Research Center for Ischemic Heart Disease, Seoul, Republic of Korea, sponsored by the Ministry of Health and Welfare, Republic of Korea.

PII: S0002-9149(09)02407-2

doi:10.1016/j.amjcard.2009.09.036

American Journal of Cardiology
Volume 105, Issue 3 , Pages 343-351, 1 February 2010